Article
Oncology
Daniel A. Fox, Deepak Bhamidipati, Tsuyoshi Konishi, Harmeet Kaur, Nancy You, Kanwal P. S. Raghav, Phillip S. Ge, Craig Messick, Benny Johnson, Van K. Morris, Jane V. Thomas, Preksha Shah, Brian K. Bednarski, Scott Kopetz, George J. Chang, Kaysia Ludford, Victoria Serpas Higbie, Michael J. Overman
Summary: This study retrospectively analyzed the endoscopic and imaging response of patients with localized dMMR CRC who received neoadjuvant immune checkpoint blockade therapy. It found discrepancies between imaging and endoscopy were common, and abnormalities could be identified despite pathological remission. Improved clinical response criteria are needed.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Raphael Colle, Sara Lonardi, Marine Cachanado, Michael J. Overman, Elena Elez, Marwan Fakih, Francesca Corti, Priya Jayachandran, Magali Svrcek, Antoine Dardenne, Baptiste Cervantes, Alex Duval, Romain Cohen, Filippo Pietrantonio, Thierry Andre
Summary: This study evaluated the prognostic value of RAS/BRAF(V600E) mutations and Lynch syndrome on immune checkpoint inhibitor-treated metastatic colorectal cancer patients with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR). The results showed that RAS/BRAF(V600E) mutations were not associated with survival, while Lynch syndrome conferred an improved progression-free survival.
Article
Oncology
Jason M. Redman, Geraldine O'Sullivan Coyne, Clay T. Reed, Ravi A. Madan, Julius Strauss, Seth J. Steinberg, Jennifer Marte, Lisa Cordes, Christopher Heery, James L. Gulley
Summary: Effective treatment options for metastatic colorectal cancer are limited, and blocking PD-1/PD-L1 interactions is not effective in enhancing immune activity in these patients.
Article
Immunology
Wenyue Zhou, Yuwen Zhou, Cheng Yi, Xinyao Shu, Guixia Wei, Xiaorong Chen, Xudong Shen, Meng Qiu
Summary: Microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) is a predictive biomarker for immune checkpoint inhibitors (ICIs) in colorectal and non-colorectal cancer populations, but not all MSI-H tumors respond to ICIs. Some patients develop hyperprogression after ICI treatment, with unclear mechanisms.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Mifen Chen, Zhenghang Wang, Zimin Liu, Ning Liu, Weijia Fang, Hangyu Zhang, Xuan Jin, Jiayi Li, Weifeng Zhao, Huajun Qu, Fanghua Song, Zhiwei Chang, Yi Li, Yong Tang, Chunlei Xu, Xiaotian Zhang, Xicheng Wang, Zhi Peng, Jinping Cai, Jian Li, Lin Shen
Summary: This study retrospectively evaluated the efficacy of anti-PD1/PD-L1 plus other drug therapy compared to chemotherapy with or without targeted therapy in MSI/dMMR gastrointestinal cancer patients who had progressed on prior anti-PD1/PD-L1 monotherapy. The results showed that anti-PD1/PD-L1 plus other drug therapy significantly improved disease control rate, progression-free survival, and overall survival, with a numerically higher objective response rate. These findings are promising and should be further confirmed in prospective trials.
Article
Oncology
Fangcen Liu, Fangfang Zhong, Huan Wu, Keying Che, Jiaochun Shi, Nandie Wu, Yao Fu, Yue Wang, Jing Hu, Xiaoping Qian, Xiangshan Fan, Weifeng Wang, Jia Wei
Summary: The prevalence and associations of B2M mutations in MSI-H/dMMR cancers were investigated in gastric cancer, colorectal cancer, and endometrial cancer. Results showed high frequencies and different forms of B2M gene alterations in these three types of cancer. Patients with B2M mutations exhibited significantly higher tumor mutational burden (TMB). Evaluation of immune checkpoint inhibitors (ICIs) should be considered for these patients.
Review
Oncology
Vito Amodio, Gianluca Mauri, Nicole M. Reilly, Andrea Sartore-Bianchi, Salvatore Siena, Alberto Bardelli, Giovanni Germano
Summary: A subset of colorectal cancers with mismatch repair deficiency are sensitive to immune checkpoint inhibitors, but some patients show primary resistance or develop acquired resistance. Changes in the Wnt and JAK-STAT signaling pathways, as well as alterations in the antigen presentation machinery, are associated with resistance to CPIs in these patients. Understanding the mechanistic basis of immune evasion in CRC provides rationale for innovative strategies to increase the subset of patients benefiting from CPIs.
Review
Oncology
Muhammet Ozer, Charan Thej Reddy Vegivinti, Masood Syed, Morgan E. E. Ferrell, Cyndi Gonzalez Gomez, Svea Cheng, Jennifer Holder-Murray, Tullia Bruno, Anwaar Saeed, Ibrahim Halil Sahin
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of mismatch repair-deficient (MMR-D)/microsatellite instability-high (MSI-H) gastrointestinal cancers. These cancers have a high mutation burden and generate mutation-associated neoantigens (MANAs). ICIs activate T-cell immunity against these cancers, leading to significant antitumor activity. The use of ICIs as neoadjuvant therapy shows great promise, as demonstrated by deep clinical and pathological responses in clinical trials.
Article
Oncology
Thierry Andre, Filippo Pietrantonio, Antonio Avallone, Mahmut Gumus, Lucjan Wyrwicz, Jong Gwang Kim, Suayib Yalcin, Mariusz Kwiatkowski, Sara Lonardi, Jakub Zolnierek, Amos Odeleye-Ajakaye, Pierre Leconte, David Fogelman, Tae Won Kim
Summary: Robust clinical activity has been observed with pembrolizumab in treating MSI-H/dMMR mCRC. However, there is still room for improvement in terms of response rate and progression-free survival. The KEYSTEP-008 trial aims to evaluate the efficacy and safety of pembrolizumab-based combination therapy compared with monotherapy in chemotherapy-refractory or previously untreated MSI-H/dMMR mCRC. Rating: 9/10
Article
Oncology
T. Ratovomanana, R. Nicolle, R. Cohen, A. Diehl, A. Siret, Q. Letourneur, O. Buhard, A. Perrier, E. Guillerm, F. Coulet, P. Cervera, P. Benusiglio, K. Labreche, R. Colle, A. Collura, E. Despras, P. Le Rouzic, F. Renaud, J. Cros, A. Alentorn, M. Touat, M. Ayadi, P. Bourgoin, C. Prunier, C. Tournigand, C. de la Fouchardiere, D. Tougeron, V. Jonchere, J. Bennouna, A. de Reynies, J. -f. Flejou, M. Svrcek, T. Andre, A. Duval
Summary: By analyzing the DNA and RNA characteristics of patients with microsatellite instability colorectal cancer, it was found that the response to immune checkpoint inhibitors can be predicted. The predictors include 19 microsatellite mutations and a set of 182 RNA markers related to non-epithelial cellular interactions. These findings are important for improving immune therapy strategies.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
T. Andre, S. Lonardi, K. Y. M. Wong, H. -J Lenz, F. Gelsomino, M. Aglietta, E. Van Cutsem, R. McDermott, A. Hill, M. B. Sawyer, A. Hendlisz, B. Neyns, S. Abdullaev, A. Memaj, M. Lei, M. Dixon, S. Kopetz, M. J. Overman, M. A. Morse
Summary: This study confirms the long-term benefit of nivolumab plus low-dose ipilimumab for previously treated patients with MSI-H/dMMR mCRC, with a manageable safety profile.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Gaia Giannone, Daniele Castaldo, Valentina Tuninetti, Giulia Scotto, Margherita Turinetto, Anna Amela Valsecchi, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Summary: The survey conducted among Italian MITO centers showed that while doctors have good knowledge of diagnostic and therapeutic innovations in EC, these innovations are not fully implemented in everyday clinical practice, except for the assessment of MSI status.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Quang Loc Bui, Leo Mas, Antoine Hollebecque, David Tougeron, Christelle de la Fouchardiere, Thomas Pudlarz, Emily Alouani, Rosine Guimbaud, Julien Taieb, Thierry Andre, Raphael Colle, Romain Cohen
Summary: This study retrospectively collected clinical data from 31 patients with dMMR/MSI mCRC. The results showed that there was no improved outcome with CT after ICI failure, but prolonged disease control was observed in some cases.
Article
Biochemistry & Molecular Biology
Agnieszka Kula, Miriam Dawidowicz, Sylwia Mielcarska, Pawel Kiczmer, Hanna Skiba, Malgorzata Krygier, Magdalena Chrabanska, Jerzy Piecuch, Monika Szrot, Julia Robotycka, Blazej Ochman, Bogumila Strzalkowska, Zenon Czuba, Elzbieta Swietochowska, Dariusz Waniczek
Summary: This study aims to investigate the correlation between HHLA2 levels and various parameters in colorectal cancer (CRC). The results demonstrate that HHLA2 is highly expressed in CRC tumor tissues compared to adjacent noncancerous tissues. The study provides valuable insights into the role of HHLA2 as a stimulatory and inhibitory immune checkpoint in CRC and suggests the potential therapeutic value of the HHLA2-KIR3DL3/TMIGD2 pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Gianluca Mauri, Erica Bonazzina, Alessio Amatu, Federica Tosi, Katia Bencardino, Viviana Gori, Daniela Massihnia, Tiziana Cipani, Francesco Spina, Silvia Ghezzi, Salvatore Siena, Andrea Sartore-Bianchi
Summary: The BRAF(V600E) mutation is detected in 8-10% of patients with metastatic colorectal cancer (mCRC) and has a poor prognostic outlook, with median overall survival below 20 months. Treatment options include immune checkpoint inhibitors (CPIs) for those with concomitant MSI-H status, and a combination of cytotoxic chemotherapy + anti-VEGF or EGFR and BRAF inhibitors for first and second line treatment, respectively. However, acquired resistance limits the potential benefits and survival remains poor. Ongoing clinical trials are exploring various strategies to improve treatment outcomes for this subset of patients.
Article
Pathology
Gianluca Russo, Francesco Pepe, Pasquale Pisapia, Lucia Palumbo, Mariantonia Nacchio, Elena Vigliar, Pierlorenzo Pallante, Paola Parente, Matteo Fassan, Paolo Graziano, Claudio Bellevicine, Giancarlo Troncone, Umberto Malapelle, Antonino Iaccarino
Summary: This article reviews the results of microsatellite instability (MSI) evaluation using a customized workflow and microfluidic system in a diagnostic routine practice over a period of 4 years. The results showed that the majority of patients with metastatic colorectal cancer (mCRC) had microsatellite stability (MSS) profile, while a minority had microsatellite high (MSI-H) profile. Similarly, in patients without colorectal cancer, both MSS and MSI-H profiles were observed.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Gastroenterology & Hepatology
Valentina Mari, Valentina Angerilli, Giada Munari, Marco Scarpa, Quoc Riccardo Bao, Salvatore Pucciarelli, Matteo Fassan, Gaya Spolverato
Summary: This review outlines the molecular pathways involved in peritoneal metastatic dissemination in gastric cancer, highlighting the lack of comprehensive understanding of the complex molecular landscape of this disease. The integration of molecular profiling and histological evaluation is recommended for risk prediction assessment of peritoneal dissemination.
DIGESTIVE DISEASES
(2023)
Article
Oncology
Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy Iveson, Steven R. Alberts, Aimery de Gramont, Alberto F. Sobrero, Daniel G. Haller, Eiji Oki, Anthony Frank Shields, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Greg Yothers, Caroline Kelly, Ioannis Boukovinas, Roberto Labianca, Frank A. Sinicrope, Ioannis Souglakos, Takayuki Yoshino, Jeffrey A. Meyerhardt, Thierry Andre, Demetris Papamichael, Julien Taieb
Summary: Whether early discontinuation of all treatment or early discontinuation of oxaliplatin could worsen the prognosis in patients with stage III CC remains unknown.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Correction
Multidisciplinary Sciences
Claudia Calabrese, Natalie R. Davidson, Deniz Demircioglu, Nuno A. Fonseca, Yao He, Andre Kahles, Kjong-Van Lehmann, Fenglin Liu, Yuichi Shiraishi, Cameron M. Soulette, Lara Urban, Liliana Greger, Siliang Li, Dongbing Liu, Marc D. Perry, Qian Xiang, Fan Zhang, Junjun Zhang, Peter Bailey, Serap Erkek, Katherine A. Hoadley, Yong Hou, Matthew R. Huska, Helena Kilpinen, Jan O. Korbel, Maximillian G. Marin, Julia Markowski, Tannistha Nandi, Qiang Pan-Hammarstrom, Chandra Sekhar Pedamallu, Reiner Siebert, Stefan G. Stark, Hong Su, Patrick Tan, Sebastian M. Waszak, Christina Yung, Shida Zhu, Philip Awadalla, Chad J. Creighton, Matthew Meyerson, B. F. Francis Ouellette, Kui Wu, Huanming Yang, Alvis Brazma, Angela N. Brooks, Jonathan Goeke, Gunnar Raetsch, Roland F. Schwarz, Oliver Stegle, Zemin Zhang
Correction
Multidisciplinary Sciences
Yilong Li, Nicola D. Roberts, Jeremiah A. Wala, Ofer Shapira, Steven E. Schumacher, Kiran Kumar, Ekta Khurana, Sebastian Waszak, Jan O. Korbel, James E. Haber, Marcin Imielinski, Joachim Weischenfeldt, Rameen Beroukhim, Peter J. Campbell
Article
Oncology
Margherita Rimini, Carles Fabregat-Franco, Mara Persano, Valentina Burgio, Francesca Bergamo, Monica Niger, Mario Scartozzi, Ilario Giovanni Rapposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Mario Rizzato, Federico Nichetti, Eleonora Lai, Alessandro Cappetta, Teresa Macarulla, Matteo Fassan, Filippo De Braud, Andrea Pretta, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study investigated the prognostic impact of IDH1 mutations in patients with advanced iCCA after progression on first-line therapies. The presence of IDH1 mutations was associated with worse overall survival and worse objective response rate in second-line therapy. IDH1 mutations were confirmed as an independent negative prognostic factor.
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Tiziana Pressiani, Fabio Piscaglia, Takashi Kumada, Lorenza Rimassa, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study aimed to establish a novel prognostic index for hepatocellular carcinoma (HCC) patients treated with atezolizumab plus bevacizumab (ABE) in the first-line setting. Using recursive partitioning analysis (RPA), the patients were categorized into high-risk, intermediate-risk, and low-risk groups. The study concluded that the ABE index allows for easy stratification of HCC patients undergoing first-line treatment with ABE.
ANTICANCER RESEARCH
(2023)
Article
Oncology
Roberto Moretto, Marco Maria Germani, Mirella Giordano, Veronica Conca, Agnese Proietti, Cristina Niccoli, Filippo Pietrantonio, Sara Lonardi, Emiliano Tamburini, Alberto Zaniboni, Alessandro Passardi, Tiziana Pia Latiano, Valentina Fanotto, Samantha Di Donato, Michele Prisciandaro, Francesca Bergamo, Gianluca Masi, Gabriella Fontanini, Clara Ugolini, Chiara Cremolini
Summary: In metastatic colorectal cancer, the expression levels of Trop-2 protein are associated with prognosis, with lower expression levels being associated with better PFS and OS. Chemotherapy intensification provides greater benefit for patients with medium/high Trop-2 expression. In contrast, the expression levels of Nectin-4 protein have no prognostic impact.
BRITISH JOURNAL OF CANCER
(2023)
Article
Hematology
Marco Pizzi, Marta Sbaraglia, Luca Dal Santo, Debora De Bartolo, Luisa Santoro, Federico Scarmozzino, Lara Mussolin, Marta Pillon, Francesco Piazza, Livio Trentin, Angelo Paolo Dei Tos
Summary: This study retrospectively reviewed 43 paired LNCB/SEB samples and found that LNCB had limited diagnostic value, with a significant number of diagnostic errors and delay. Therefore, SEB should still be considered as the gold standard procedure.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Article
Oncology
Grazia Vernaci, Edoardo Vincenzo Savarino, Ilaria Patuzzi, Sonia Facchin, Fabiana Zingone, Davide Massa, Giovanni Faggioni, Tommaso Giarratano, Federica Miglietta, Gaia Griguolo, Matteo Fassan, Marcello Lo Mele, Elisa Gasparini, Giancarlo Bisagni, Valentina Guarneri, Maria Vittoria Dieci
Summary: This article evaluates the feasibility of analyzing the gut microbiome in patients with early stage triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy, and explores its impact on treatment response and clinicopathologic factors. The study suggests that analyzing the gut microbiome may have potential significance in early TNBC, but further investigation is needed to understand its complex correlation with immunity and cancer.
Article
Oncology
G. Martini, D. Ciardiello, V. Famiglietti, D. Rossini, C. Antoniotti, T. Troiani, S. Napolitano, L. Esposito, T. P. Latiano, E. Maiello, M. Del Re, S. Lonardi, G. Aprile, D. Santini, G. Masi, A. Avallone, N. Normanno, F. Pietrantonio, C. Pinto, F. Ciardiello, C. Cremolini, E. Martinelli
Summary: The rechallenge strategy of cetuximab in third-line treatment of RAS/BRAF WT ctDNA mCRC patients shows promising results in terms of median PFS and OS. Skin rash is more frequently reported in CAVE trial, while increased incidence of hematological toxicities is observed in CRICKET trial. This therapy requires further investigation for its potential benefits and side effects.
Article
Oncology
Claire Gallois, Matteo Landi, Julien Taieb, Marine Sroussi, Bahar Saberzadeh-Ardestani, Antoine Cazelles, Sara Lonardi, Francesca Bergamo, Rossana Intini, Giulia Maddalena, Filippo Pietrantonio, Francesca Corti, Margherita Ambrosini, Antonia Martinetti, Marco Maria Germani, Chiara Boccaccio, Guglielmo Vetere, Sophie Mouillet-Richard, Aurelien de Reynies, Frank A. Sinicrope, Chiara Cremolini, Pierre Laurent-Puig
Summary: In this study, a transcriptomic classification was used to identify three groups of microsatellite instability metastatic colorectal cancers (MSI mCRC) with different compositions of tumor microenvironment and proliferative capacities. The group with high stromal and low proliferation showed a poorer prognosis with immune checkpoint inhibitor treatment.
CLINICAL CANCER RESEARCH
(2023)
Article
Pathology
Albino Eccher, Angelo Paolo Dei Tos, Aldo Scarpa, Vincenzo L'Imperio, Enrico Munari, Giancarlo Troncone, Antonio Giuseppe Naccarato, Davide Seminati, Fabio Pagni
Summary: Despite reluctance to invest and challenges in estimating supporting costs, optimizing archives is becoming a hot topic in pathology laboratory management. Historically, archives were inadequate for securely storing and organizing tissue specimens, leading to risks for patients' health and legal consequences for pathologists.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Oncology
Laura Bonanno, Martina Lorenzi, Davide Massa, Mattia De Nuzzo, Valentina Angerilli, Fabiana Zingone, Brigida Barberio, Alberto Russi, Fabio Girardi, Alessandra Ferro, Alessandro Dal Maso, Stefano Frega, Giulia Pasello, Angelo Paolo Dei Tos, Marina Coppola, Matteo Fassan, Edoardo Vincenzo Savarino, Valentina Guarneri
Summary: This study collected real-world data on the occurrence of immune-mediated diarrhea and colitis in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors, and assessed the clinical impact of a multidisciplinary approach on the management of this adverse event.
Review
Oncology
Alessandro Massano, Luisa Bertin, Fabiana Zingone, Andrea Buda, Pierfrancesco Visaggi, Lorenzo Bertani, Nicola de Bortoli, Matteo Fassan, Marco Scarpa, Cesare Ruffolo, Imerio Angriman, Cristina Bezzio, Valentina Casini, Davide Giuseppe Ribaldone, Edoardo Vincenzo Savarino, Brigida Barberio
Summary: This review summarizes the evidence on the association between inflammatory bowel disease (IBD) and extraintestinal cancers (EICs), as well as the safety and management of immunomodulators and biologics for IBD patients with prior or current EICs.